{
    "ticker": "ARBEW",
    "name": "Arbutus Biopharma Corporation",
    "description": "Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing innovative antiviral therapies for the treatment of chronic hepatitis B virus (HBV) infection. Founded in 2001 and headquartered in Langley, British Columbia, Canada, Arbutus is committed to addressing the unmet medical need for effective treatments that can reduce or eliminate HBV from infected individuals. The company's proprietary pipeline includes several drug candidates targeting different aspects of the HBV lifecycle, including RNA interference and core protein modulation. Arbutus has established strategic collaborations to advance its research and development efforts, and it is driven by a strong scientific foundation and a dedicated team with extensive experience in drug development. The company aims to provide solutions that significantly improve the quality of life for patients suffering from HBV and ultimately contribute to the eradication of the virus. Arbutus is also exploring other viral targets, leveraging its expertise in nucleic acid-based therapeutics and drug development processes. The company's mission is to transform the treatment landscape for viral infections through groundbreaking therapies that not only manage the disease but also offer potential cures.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Langley, British Columbia, Canada",
    "founded": "2001",
    "website": "https://www.arbutusbio.com",
    "ceo": "William Collier",
    "social_media": {
        "twitter": "https://twitter.com/arbutusbio",
        "linkedin": "https://www.linkedin.com/company/arbutus-biopharma/"
    },
    "investor_relations": "https://ir.arbutusbio.com",
    "key_executives": [
        {
            "name": "William Collier",
            "position": "CEO"
        },
        {
            "name": "Gregory P. McHugh",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Antiviral Therapies",
            "products": [
                "AB-423",
                "AB-729"
            ]
        }
    ],
    "seo": {
        "meta_title": "Arbutus Biopharma Corporation | Innovative Antiviral Therapies",
        "meta_description": "Explore Arbutus Biopharma Corporation, a leader in developing antiviral treatments for chronic hepatitis B. Learn about our innovative pipeline and commitment to patient care.",
        "keywords": [
            "Arbutus Biopharma",
            "Hepatitis B",
            "Antiviral Therapy",
            "Biopharmaceuticals",
            "Chronic HBV Treatment"
        ]
    },
    "faq": [
        {
            "question": "What is Arbutus Biopharma focused on?",
            "answer": "Arbutus Biopharma is focused on developing innovative antiviral therapies for the treatment of chronic hepatitis B virus infection."
        },
        {
            "question": "Who is the CEO of Arbutus Biopharma?",
            "answer": "William Collier is the CEO of Arbutus Biopharma Corporation."
        },
        {
            "question": "Where is Arbutus Biopharma headquartered?",
            "answer": "Arbutus Biopharma is headquartered in Langley, British Columbia, Canada."
        },
        {
            "question": "What are Arbutus Biopharma's main products?",
            "answer": "Arbutus Biopharma's main products include AB-423 and AB-729, which are in development for the treatment of HBV."
        },
        {
            "question": "When was Arbutus Biopharma founded?",
            "answer": "Arbutus Biopharma was founded in 2001."
        }
    ],
    "competitors": [
        "GILD",
        "VIR",
        "BMY"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "VRTX",
        "KITE"
    ]
}